( MEMY) vaulted more than 21% in after-hours trading Thursday as the Montvale, N.J., biotech completed enrollment for a phase IIa clinical trial of Mem 1003, one of its proposed treatments for Alzheimer's disease. Memory Pharma expects top-line results to be in by the fourth quarter. Shares of the small-cap company were up 35 cents to $1.98.
saw mounting profits for the quarter ended Feb. 28 that bested Wall Street estimates. The San Diego-based company earned $8.9 million, or 52 cents a share, on $79.3 million in sales, compared with 43-cent per-share profits last year. Analysts polled by Thomson Financial were seeking 46 cents a share on revenue of $78.3 million. Shares were rising $2.02, or 6.3%, to $33.91 in recent after-hours action.
slid 18% after lowering its outlook for the quarter ended April 28. The Brookings, S.D., maker of scoreboards and other visual display products now foresees profits of between 6 cents and 10 cents a share on revenue ranging between $101 million and $105 million. Prior estimates had pegged per-share earnings at 12 cents to 19 cents on sales of $106 million to $118 million. Shares were losing $5.06, to $22.85.
( KRY) slipped after the Toronto-based gold miner offered 12.5 million shares in Canada at $3.69 apiece ($4.25 Canadian), with an underwriter's option for about another 1.9 million shares to cover any overallotments. Proceeds will pay for expenses relating to one of its Venezuelan projects, Las Cristinas, as well as for debt repayment and general corporate purposes. Shares were dipping 7 cents, or 1.7%, to $4.03 in recent late trading